Sinclair IS Pharma joins forces with Biocodex to crack new markets

Sinclair IS Pharma has signed a 10-year deal with Biocodex to expand its dermatology portfolio in Russia, Turkey and Europe's Benelux countries.

Biocodex, an independent French pharmaceutical company, will support in the importation and distribution of Sinclair products to wholesalers. The company will also facilitate in marketing, advertising, and promotion of commodities to clinicians and pharmacies.

Sinclair - a London-based pharmaceutical firm focused on treatments in dermatology, wound care and oncology support - expects the new partnership will help the organisation crack new markets.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

"This partnership with Biocodex supports our growth strategy to create relationships with strong strategic partners and move our product portfolio into fast-growing, emerging markets" Chris Spooner, Chief Executive Officer of Sinclair, said.

"We already have a successful distribution partnership with Biocodex in Turkey, which provides the foundation for this new multi-product, multi-country arrangement."

Sinclair products which are part of the agreement include: Kelo-cote silicone-gel scar reduction range; Sculptra collagen stimulator for deep tissue regeneration; Papulex for acne; Bio-Taches for hyperpigmentation disorders; Atopiclair for atopic dermatitis; and Sebclair for the treatment of seborrhoeic dermatitis.

RD